Drug Profile
Pulrodemstat - Celgene Corporation
Alternative Names: CC-90011Latest Information Update: 08 Mar 2024
Price :
$50
*
At a glance
- Originator Quanticel Pharmaceuticals
- Developer Celgene Corporation
- Class Amines; Antineoplastics; Fluorobenzenes; Nitriles; Phenyl ethers; Piperidines; Pyrimidinones; Small molecules
- Mechanism of Action Lysine specific demethylase 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Non-small cell lung cancer; Small cell lung cancer
- Discontinued Acute myeloid leukaemia; Non-Hodgkin's lymphoma; Prostate cancer; Solid tumours
Most Recent Events
- 19 Dec 2023 Celgene completes a phase II trial in Non-small cell lung cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) in USA, United Kingdom, Poland, France, Italy, Spain (PO) (NCT04350463)
- 19 Dec 2023 Celgene completes a phase II trial in Small cell lung cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) in USA, United Kingdom, Poland, France, Italy, Spain (PO) (NCT04350463)
- 24 Oct 2023 Safety and efficacy data from a phase II trial in Non-small cell lung cancer presented at the at 24th World Conference on Lung Cancer (WCLC-2023)